Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01278030 · ClinicalTrials.gov registry record · NA
Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 78
- Enrollment target
NCT01278030 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 78 participants.
The verdict
NCT01278030, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that cardiac resynchronization therapy (CRT) responder rate can be improved by 3-dimensional (3D) echo-guided left ventricular (LV) lead placement compared to traditional LV lead placement.
Interventions
- PROCEDURE 3D echo-guided LV lead placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2010-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01278030
The ClinicalTrials.gov registry entry for NCT01278030 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3D echo-guided LV lead placement is the first listed.
NCT01278030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01278030 about?
NCT01278030 is a clinical study titled "Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates". The purpose of this study is to demonstrate that cardiac resynchronization therapy (CRT) responder rate can be improved by 3-dimensional (3D) echo-guided left ventricular (LV) lead placement compared to traditional LV lead placement.
What is the current status of trial NCT01278030?
This trial is currently completed. It is a NA study. The enrollment target is 78 participants. The study started on 2010-08.
What interventions are being tested in trial NCT01278030?
The interventions under investigation include: 3D echo-guided LV lead placement (PROCEDURE).
Who is sponsoring clinical trial NCT01278030?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.